Statin Use Is Associated with Reduced Risk of Haematological Malignancies: Evidence from a Meta-Analysis
Open Access
- 31 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e87019
Abstract
Several observational studies have shown that statin use may modify the risk of haematological malignancies. To quantify the association between statin use and risk for haematological malignancies, we performed a detailed meta-analysis of published studies regarding this subject. We conducted a systematic search of multiple databases including PubMed, Embase, and Cochrane Library Central database up to July 2013. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed. A total of 20 eligible studies (ten case-control studies, four cohort studies, and six RCTs) reporting 1,139,584 subjects and 15,297 haematological malignancies cases were included. Meta-analysis showed that statin use was associated with a statistically significant 19% reduction in haematological malignancies incidence (RR = 0.81, 95% CI [0.70, 0.92]). During subgroup analyses, statin use was associated with a significantly reduced risk of haematological malignancies among observational studies (RR = 0.79, 95% CI [0.67, 0.93]), but not among RCTs (RR = 0.92, 95% CI [0.77, 1.09]). Based on this comprehensive meta-analysis, statin use may have chemopreventive effects against haematological malignancies. More studies, especially definitive, randomized chemoprevention trials are needed to confirm this association.Keywords
This publication has 46 references indexed in Scilit:
- Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational StudiesPLOS ONE, 2012
- Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based StudyPreventing Chronic Disease, 2012
- Exposure to statins and risk of common cancers: a series of nested case-control studiesBMC Cancer, 2011
- Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPHCancer Epidemiology, Biomarkers & Prevention, 2006
- Use of hydroxy‐methyl‐glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignanciesCancer Science, 2006
- Controlling the risk of spurious findings from meta‐regressionStatistics in Medicine, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-upThe Lancet, 2002
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986